Piramal Pharma Ltd (PPLPHARMA) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported a year-over-year revenue decline, primarily attributed to significant inventory destocking by a single large CDMO customer for an on-patent commercial product.
- Despite the revenue shortfall, the company's focus on cost optimization and operational excellence initiatives helped partially mitigate the negative impact on EBITDA.
- The Consumer Healthcare (PCH) business was a bright spot, delivering sustained growth of 15% during the quarter, driven by a robust 20% growth in its power brands.
- The company successfully reduced its net debt by 228 crores compared to March 2025, maintaining a net debt-to-EBITDA ratio of less than 3x, supported by tight control over working capital and CapEx.
- A strong quality and compliance record was maintained, with zero Official Action Indicated (OAI) findings and the successful closure of 19 inspections, including a USFDA inspection at the Aurora, Canada facility without any observations.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.